医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Marinomed Granted Chinese Patent for Antiviral Polymer

2012年11月19日 AM09:25
このエントリーをはてなブックマークに追加


 

VIENNA

Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, today announced that it has been granted Chinese Patent No. CN101678040, entitled ‘Antiviral polymer’, by the Chinese patent office. The patent covers the use of a specific polymer for the prevention and treatment of rhinovirus infections.

Dr. Andreas Grassauer, CEO and co-founder of Marinomed, commented:

“The national granting of this patent is an important further step in protecting Marinomed’s intellectual property and know-how around our anti-viral product portfolio based on our mavirex technology platform. Furthermore this patent contributes value in the out-licensing of our products or technology to partner companies in China.”

Marinomed has an anti-viral product portfolio for the prevention and treatment of common cold and influenza. The products include the patent protected polymer Carragelose®; a polymer of the mavirex technology platform. Marinomed’s anti-viral OTC portfolio is already marketed in- and out-side of the EU. The lead product is an anti-viral nasal spray against common cold for adults and children starting from age 1, pregnant and breastfeeding women.

– ends –

About Marinomed Biotechnologie GmbH

Marinomed Biotechnologie GmbH was founded in 2006 and develops therapies against respiratory diseases based on an innovative anti-viral respiratory technology platform. The usability of this safe and effective technology has been proven by its first marketed product: an anti-viral nasal spray. The huge potential of the technology is reflected by Marinomed’s additional products concentrating on influenza, combination products for asthmatics and other high-risk patients. In addition, the Company develops a novel treatment against type I allergy and autoimmune diseases. Marinomed Biotechnologie GmbH is a spin-off from the Veterinary University Vienna and is located in Vienna, Austria.

For further information, please visit the website at www.marinomed.com.

CONTACT

Marinomed Biotechnologie GmbH
Johanna Uhlmann
Business
Development
Tel: +43 (0)1 25077 4460
johanna.uhlmann@marinomed.com
or
College
Hill Life Sciences

Dr. Robert Mayer
Account Director
T:
+44 (0)207 866 7868
robert.mayer@collegehill.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Philip Morris International Launches Next Generation of IQOS, the World’s Leading Heated Tobacco Product
  • PotNetwork Holdings, Inc.第三季度业绩创纪录,营收超过610万美元
  • ポットネットワーク・ホールディングスが610万ドルを超える収益で過去最高の第3四半期を終える
  • ポットネットワーク・ホールディングスがSEC報告会社となるためにフォーム10を提出
  • Sinovac Granted Interim Injunctive Relief Regarding Filings Bearing a Falsified Company Seal and Forged Board Member Signatures